Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
GPR42 Biologics Sequence Review Report 2026: G protein-coupled receptor 42 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
GPR42 Biologics Sequence Review Report 2026: G protein-coupled receptor 42 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of GPR42 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CLDN3 Biologics Sequence Review Report 2026: Claudin-3 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CLDN3 Biologics Sequence Review Report 2026: Claudin-3 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CLDN3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
TLR4 Biologics Sequence Review Report 2026: Toll-like receptor 4 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
TLR4 Biologics Sequence Review Report 2026: Toll-like receptor 4 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of TLR4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IL1B Biologics Sequence Review Report 2026: Interleukin-1 beta Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IL1B Biologics Sequence Review Report 2026: Interleukin-1 beta Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of IL1B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IL1A Biologics Sequence Review Report 2026: Interleukin-1 alpha Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IL1A Biologics Sequence Review Report 2026: Interleukin-1 alpha Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of IL1A protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IL18BP Biologics Sequence Review Report 2026: Interleukin-18-binding protein Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IL18BP Biologics Sequence Review Report 2026: Interleukin-18-binding protein Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of IL18BP protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
FGF19 Biologics Sequence Review Report 2026: Fibroblast growth factor 19 Similarity and Patent-Risk Signals
8 min read
FGF19 Biologics Sequence Review Report 2026: Fibroblast growth factor 19 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of FGF19 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CXCL14 Biologics Sequence Review Report 2026: C-X-C motif chemokine 14 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CXCL14 Biologics Sequence Review Report 2026: C-X-C motif chemokine 14 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CXCL14 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
GPR37 Biologics Sequence Review Report 2026: Prosaposin receptor GPR37 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
GPR37 Biologics Sequence Review Report 2026: Prosaposin receptor GPR37 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of GPR37 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
TNFRSF13B Biologics Sequence Review Report 2026: Tumor necrosis factor receptor superfamily member 13B Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
TNFRSF13B Biologics Sequence Review Report 2026: Tumor necrosis factor receptor superfamily member 13B Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of TNFRSF13B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
TNFRSF10C Biologics Sequence Review Report 2026: Tumor necrosis factor receptor superfamily member 10C Similarity and Patent-Risk Signals
8 min read
TNFRSF10C Biologics Sequence Review Report 2026: Tumor necrosis factor receptor superfamily member 10C Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of TNFRSF10C protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
TNFRSF10B Biologics Sequence Review Report 2026: Tumor necrosis factor receptor superfamily member 10B Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
TNFRSF10B Biologics Sequence Review Report 2026: Tumor necrosis factor receptor superfamily member 10B Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of TNFRSF10B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →